Argatroban

CHEMBL1166 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

508.6 g/mol

LogP

1.3

Phase

4

A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.

Peso Molecular

508,6000 g/mol

LogP

1,30

TPSA

189,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Stroke Deep Vein Thrombosis / Pulmonary Embolism

Mecanismo de Ação

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1

InChI

InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1

Molecular Formula

C23H36N6O5S

HBD / HBA

5 / 8

Ligações Rotacionáveis

9

Átomos Pesados

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Yes, Argatroban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1166. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 92722. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Argatroban no PillFYI

Estrutura

Dados Rápidos

Fórmula: C23H36N6O5S

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.